Skip to content
Flyout Menu
  • About Us
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
      • Boston
      • Manchester
      • Hyderabad
      • Bidar
  • Our Capabilities
    • Discovery
      • CADD & Structural Biology
      • Compound Management
      • DMPK (Drug Metabolism & Pharmacokinetics)
      • In Vitro Biology
      • In Vivo Pharmacology
      • Integrated Drug Discovery (IDD)
      • Safety & Toxicology
      • Synthetic & Medicinal Chemistry
    • Drug Substance Development
      • Analytical Development
      • Developability & Pre-Formulation
      • Particle Science & Engineering
      • Process Development
      • Process Engineering
      • Discovery Process Chemistry
    • Drug Substance Manufacturing
      • Engineering Technologies
      • Infrastructure
      • Product Types
    • New Modalities
      • Antibody–Drug Conjugates
      • Lipids
      • Oligos
      • Peptides
    • Formulations
      • Clinical Formulation Supplies
      • New Chemical Entity (NCE) formulation development
  • Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
  • Knowledge Hub
    • Newsroom
    • Newsroom – Blogs
    • Newsroom – Case Studies
  • Investors
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
  • Careers
  • Contact us
  • About Us
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
    • – Boston
    • – Manchester
    • – Hyderabad
    • – Bidar
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
    • – Boston
    • – Manchester
    • – Hyderabad
    • – Bidar
  • Our Capabilities
    • Discovery
    • Integrated Drug Discovery (IDD)
    • CADD & Structural Biology
    • Synthetic & Medicinal Chemistry
    • In Vitro Biology
    • DMPK (Drug Metabolism & Pharmacokinetics)
    • In Vivo Pharmacology
    • Safety & Toxicology
    • Compound Management
    • Discovery
    • Integrated Drug Discovery (IDD)
    • CADD & Structural Biology
    • Synthetic & Medicinal Chemistry
    • In Vitro Biology
    • DMPK (Drug Metabolism & Pharmacokinetics)
    • In Vivo Pharmacology
    • Safety & Toxicology
    • Compound Management
    • Drug Substance Development
    • Discovery Process Chemistry
    • Process Development
    • Analytical Development
    • Process Engineering
    • Particle Science & Engineering
    • Developability & Pre-Formulation
    • Drug Substance Development
    • Discovery Process Chemistry
    • Process Development
    • Analytical Development
    • Process Engineering
    • Particle Science & Engineering
    • Developability & Pre-Formulation
    • Drug Substance Manufacturing
    • Product Types
    • Infrastructure
    • Engineering Technologies
    • Formulations
    • New Chemical Entity (NCE) formulation development
    • Clinical Formulation Supplies
    • Drug Substance Manufacturing
    • Product Types
    • Infrastructure
    • Engineering Technologies
    • Formulations
    • New Chemical Entity (NCE) formulation development
    • Clinical Formulation Supplies
    • New Modalities
    • Antibody–Drug Conjugates
    • Peptides
    • Oligos
    • New Modalities
    • Antibody–Drug Conjugates
    • Peptides
    • Oligos
  • Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
  • Knowledge Hub
    • Newsroom
    • Blogs
    • Case Studies
    • Newsroom
    • Blogs
    • Case Studies
  • Investors
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
  • Careers
  • Contact us
  • About Us
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
    • – Boston
    • – Manchester
    • – Hyderabad
    • – Bidar
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
    • – Boston
    • – Manchester
    • – Hyderabad
    • – Bidar
  • Our Capabilities
    • Discovery
    • Integrated Drug Discovery (IDD)
    • CADD & Structural Biology
    • Synthetic & Medicinal Chemistry
    • In Vitro Biology
    • DMPK (Drug Metabolism & Pharmacokinetics)
    • In Vivo Pharmacology
    • Safety & Toxicology
    • Compound Management
    • Discovery
    • Integrated Drug Discovery (IDD)
    • CADD & Structural Biology
    • Synthetic & Medicinal Chemistry
    • In Vitro Biology
    • DMPK (Drug Metabolism & Pharmacokinetics)
    • In Vivo Pharmacology
    • Safety & Toxicology
    • Compound Management
    • Drug Substance Development
    • Discovery Process Chemistry
    • Process Development
    • Analytical Development
    • Process Engineering
    • Particle Science & Engineering
    • Developability & Pre-Formulation
    • Drug Substance Development
    • Discovery Process Chemistry
    • Process Development
    • Analytical Development
    • Process Engineering
    • Particle Science & Engineering
    • Developability & Pre-Formulation
    • Drug Substance Manufacturing
    • Product Types
    • Infrastructure
    • Engineering Technologies
    • Formulations
    • New Chemical Entity (NCE) formulation development
    • Clinical Formulation Supplies
    • Drug Substance Manufacturing
    • Product Types
    • Infrastructure
    • Engineering Technologies
    • Formulations
    • New Chemical Entity (NCE) formulation development
    • Clinical Formulation Supplies
    • New Modalities
    • Antibody–Drug Conjugates
    • Peptides
    • Oligos
    • New Modalities
    • Antibody–Drug Conjugates
    • Peptides
    • Oligos
  • Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
  • Knowledge Hub
    • Newsroom
    • Blogs
    • Case Studies
    • Newsroom
    • Blogs
    • Case Studies
  • Investors
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
  • Careers
  • Contact us
  • About Us
    Main Menu
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
      • Boston
      • Manchester
      • Hyderabad
      • Bidar
  • Our Capabilities
    Main Menu
    • Discovery
      • Integrated Drug Discovery (IDD)
      • CADD & Structural Biology
      • Synthetic & Medicinal Chemistry
      • In Vitro Biology
      • DMPK (Drug Metabolism & Pharmacokinetics)
      • In Vivo Pharmacology
      • Safety & Toxicology
      • Compound Management
    • Drug Substance Development
      • Discovery Process Chemistry
      • Process Development
      • Analytical Development
      • Process Engineering
      • Particle Science & Engineering
      • Developability & Pre-Formulation
    • Drug Substance Manufacturing
      • Product Types
      • Infrastructure
      • Engineering Technologies
    • Formulations
      • New Chemical Entity (NCE) formulation development
      • Clinical Formulation Supplies
    • New Modalities
      • Antibody–Drug Conjugates
      • Peptides
      • Oligos
  • Sustainability
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
  • Knowledge Hub
    • Newsroom
    • Blogs
    • Case Studies
    • Newsroom
    • Blogs
    • Case Studies
  • Investors
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
  • Careers
  • Contact us
  • About Us
    Main Menu
    • Overview
    • The Sai Way
    • Leadership
    • Quality
    • Facilities
      • Boston
      • Manchester
      • Hyderabad
      • Bidar
  • Our Capabilities
    Main Menu
    • Discovery
      • Integrated Drug Discovery (IDD)
      • CADD & Structural Biology
      • Synthetic & Medicinal Chemistry
      • In Vitro Biology
      • DMPK (Drug Metabolism & Pharmacokinetics)
      • In Vivo Pharmacology
      • Safety & Toxicology
      • Compound Management
    • Drug Substance Development
      • Discovery Process Chemistry
      • Process Development
      • Analytical Development
      • Process Engineering
      • Particle Science & Engineering
      • Developability & Pre-Formulation
    • Drug Substance Manufacturing
      • Product Types
      • Infrastructure
      • Engineering Technologies
    • Formulations
      • New Chemical Entity (NCE) formulation development
      • Clinical Formulation Supplies
    • New Modalities
      • Antibody–Drug Conjugates
      • Peptides
      • Oligos
  • Sustainability
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
    • Sustainability
    • Health, Safety and Environment
    • Corporate Social Responsibility
  • Knowledge Hub
    • Newsroom
    • Blogs
    • Case Studies
    • Newsroom
    • Blogs
    • Case Studies
  • Investors
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
    • Investor Relations
    • Financial Information
    • Annual reports
    • Corporate Governance
    • Shareholder Services
    • Disclosures
  • Careers
  • Contact us

Process Engineering & Technology Transfer

At Sai Life Sciences, our Process Engineering & Technology Transfer capabilities are designed to ensure efficient process development, seamless pilot studies, and predictable scale-up to commercial manufacturing. We combine thoughtful planning, accurate technical assessment, and disciplined resource management to deliver robust, scalable processes that meet quality, timeline, and cost expectations.

From early design to plant readiness, we apply structured process engineering principles supported by digital tools and advanced modeling platforms. Our approach integrates process design, equipment evaluation, line balancing, and cycle time optimization—ensuring that scale-up is not merely a transfer of chemistry, but a well-engineered transition to reliable manufacturing.

Elements of Our Approach

Deeper Understanding at the Proposal Stage

We begin with a comprehensive evaluation of the process—assessing reaction pathways, material attributes, batch size, equipment selection, and facility fit. By aligning process requirements with plant capabilities early, we minimize downstream risk. Detailed line balancing and cycle-time optimization ensure efficient utilization of assets from pilot to commercial scale.

Close Collaboration with Process R&D

Our engineering teams work in lockstep with Process R&D to build robustness into every stage of development. Whether supporting pre-clinical, early-phase, late-phase, or commercial molecules, we ensure scalability, reproducibility, and regulatory readiness across diverse molecular classes.

Pilot Plant as a Miniature Commercial Facility

Our pilot facility mirrors the operating philosophy, automation systems, and control strategies of commercial plants. This enables real-world validation of process parameters, first-hand troubleshooting experience, and smoother technology transfer with minimized surprises at full scale.

Advanced Modeling & Manufacturing Technologies

We leverage simulation tools and emerging manufacturing technologies to replace conventional approaches where beneficial—enhancing productivity, reducing variability, and accelerating delivery timelines.

Consult an expert

Elements of Our Approach

Deeper Understanding at the Proposal Stage

We begin with a comprehensive evaluation of the process—assessing reaction pathways, material attributes, batch size, equipment selection, and facility fit. By aligning process requirements with plant capabilities early, we minimize downstream risk. Detailed line balancing and cycle-time optimization ensure efficient utilization of assets from pilot to commercial scale.

Close Collaboration with Process R&D

Our engineering teams work in lockstep with Process R&D to build robustness into every stage of development. Whether supporting pre-clinical, early-phase, late-phase, or commercial molecules, we ensure scalability, reproducibility, and regulatory readiness across diverse molecular classes.

Pilot Plant as a Miniature Commercial Facility

Our pilot facility mirrors the operating philosophy, automation systems, and control strategies of commercial plants. This enables real-world validation of process parameters, first-hand troubleshooting experience, and smoother technology transfer with minimized surprises at full scale.

Advanced Modeling & Manufacturing Technologies

We leverage simulation tools and emerging manufacturing technologies to replace conventional approaches where beneficial—enhancing productivity, reducing variability, and accelerating delivery timelines.

Consult an expert

Digital Solutions for Process Efficiency & Risk Management

Beyond commercial software, we have developed in-house digital solutions that enhance equipment selection, process visualization, and risk identification—strengthening decision-making across technology transfer programs.

Advanced Technologies for Improved Efficiency

We leverage a suite of advanced continuous‑processing technologies that empower our partners with faster development, smarter manufacturing, and consistently higher‑quality outcomes:

  • Plug Flow Reactors (PFRs) that deliver precise, high‑efficiency reactions designed for speed and consistency
  • CSTRs in series enabling seamless, steady‑state production ideal for scale‑up and commercial reliability
  • Continuous carbon cartridge treatment for cleaner processes and superior product purity
  • Static mixers that ensure optimal blending, reduced variability, and streamlined throughput
  • Advanced liquid–liquid extraction for high‑performance separation and purification
  • Plug flow crystallization that drives controlled crystal formation and exceptional uniformity
  • Tangential flow filtration enables continuous, high‑performance filtration and concentration of biomolecules and other intermediates, delivering scalable processing and high product recovery.
  • Wet milling: Uses high‑energy wet milling technique to achieve precise particle‑size reduction that enhances dispersion, uniformity, and downstream performance.
  • Short‑path distillation to efficiently purify heat‑sensitive or high‑boiling compounds, achieving high purity under reduced pressures.

Digitalization & Software-Enabled Engineering

Modelling Framework

We deploy a structured modelling approach tailored to project goals and data availability:

  • Mechanistic Models: Reaction Lab, Aspen Plus, MixIT
  • Empirical Models: Design Expert, Dynochem
  • Hybrid Models: AI/ML-based frameworks

Model selection depends on development stage, interpretability needs, and risk profile.

Data Collection & Governance

Data is captured from lab trials, HMI/SCADA systems, and PAT tools, then cleaned, normalized, and stored in structured formats such as ELNs and secure cloud repositories. Models are preserved as project assets, enabling reuse and knowledge continuity.

Lifecycle Use of Models

Engineers actively deploy models during lab-scale studies, scale-up planning, and troubleshooting. Bottlenecks, variability sources, and process gaps are identified through structured analysis. Models are documented, templated (e.g., DoE frameworks, kinetic model structures), and continuously refined through validation feedback.

Tools & Collaboration

We use platforms such as Aspen Plus, Dynochem, and MixIT for process and scale-up modeling. Model outputs are shared through secure digital folders, PDF reports, SharePoint access, or API-enabled integration—ensuring transparency and collaborative decision-making.

Resources

Dhruva – Intelligent Process Flow & Risk Evaluation Platform

  • May 13, 2026
View Resource

Contribution to ISPE Good Practice Guide: Technology Transfer

  • May 13, 2026
View Resource

De‑Risks Scale‑Up from Lab to Plant

Consult an expert

Talk to us

Business Inquiries

Contact Us

Careers

Explore opportunities

General Inquiries

contact@sailife.com

Newsletter

DS-7, IKP Knowledge Park,
Turkapally Village, Shameerpet Mandal,
Medchal-Malkajgiri District-500078,
Telangana, India

Company
Main Menu
  • About Us
  • Investors
  • Careers
  • Contact us
Our Capabilities
Main Menu
  • Discovery
  • Drug Substance Development
  • Drug Substance Manufacturing
  • Formulations
  • New Modalities
Knowledge Hub
Main Menu
  • News
  • Blogs
  • Case Studies
Legal
Main Menu
  • Privacy Policy
  • Cookie Policy
  • Terms & Conditions

© 2026 Sai Life Sciences All rights reserved.

Facebook-f Instagram Linkedin-in X-twitter Youtube